Results 21 to 30 of about 279,069 (213)

Chemoresponse of de novo Acute Myeloid Leukemia to “7+3” Induction can Be Predicted by c-Myc-facilitated Cytogenetics

Frontiers in Pharmacology, 2021
Background: Identifying patients with de novo acute myeloid leukemia (AML) who will probably respond to the “7 + 3” induction regimen remains an unsolved clinical challenge.
Tzu-Hung Hsiao, Ren Ching Wang, Ren Ching Wang, Tsai-Jung Lu, Chien-Hung Shih, Yu-Chen Su, Jia-Rong Tsai, Pei-Pei Jhan, Cai-Sian Lia, Han-Ni Chuang, Kuang-Hsi Chang, Kuang-Hsi Chang, Kuang-Hsi Chang, Chieh-Lin Teng, Chieh-Lin Teng, Chieh-Lin Teng   +15 more
doaj   +1 more source

c-myc Amplification Is Frequent in Esophageal Adenocarcinoma and Correlated with the Upregulation of VEGF-A Expression

Neoplasia: An International Journal for Oncology Research, 2006
BACKGROUND: Deregulation of c-myc plays a major role in the carcinogenesis of human malignancies. We investigated the amplification of the c-myc gene in a surgical series of Barrett cancers. METHODS: Primary resected esophageal (Barrett) adenocarcinomas (
Burkhard H.A. von Rahden, Hubert J. Stein, Franziska Pühringer-Oppermann, Mario Sarbia   +3 more
doaj   +1 more source

Impact of c-MYC expression on proliferation, differentiation, and risk of neoplastic transformation of human mesenchymal stromal cells

Stem Cell Research & Therapy, 2019
Background Mesenchymal stromal cells isolated from bone marrow (MSC) represent an attractive source of adult stem cells for regenerative medicine. However, thorough research is required into their clinical application safety issues concerning a risk of ...
Svitlana Melnik, Nadine Werth, Stephane Boeuf, Eva-Maria Hahn, Tobias Gotterbarm, Martina Anton, Wiltrud Richter   +6 more
doaj   +1 more source

The polyoma virus large T binding protein p150 is a transcriptional repressor of c-MYC. [PDF]

PLoS ONE, 2012
p150, product of the SALL2 gene, is a binding partner of the polyoma virus large T antigen and a putative tumor suppressor. p150 binds to the nuclease hypersensitive element of the c-MYC promoter and represses c-MYC transcription.
Chang Kyoo Sung, Hyungshin Yim, Hongcang Gu, Dawei Li, Erik Andrews, Sekhar Duraisamy, Cheng Li, Ronny Drapkin, Thomas Benjamin   +8 more
doaj   +1 more source

c-Myc Suppression of DNA Double-strand Break Repair

Neoplasia: An International Journal for Oncology Research, 2012
c-Myc is a transcriptional factor that functions as a central regulator of cell growth, proliferation, and apoptosis. Overexpression of c-Myc also enhances DNA double-strand breaks (DSBs), genetic instability, and tumorigenesis. However, the mechanism(s)
Zhaozhong Li, Taofeek K. Owonikoko, Shi-Yong Sun, Suresh S. Ramalingam, Paul W. Doetsch, Zhi-Qiang Xiao, Fadlo R. Khuri, Walter J. Curran, Xingming Deng   +8 more
doaj   +1 more source

Humanized c-Myc mouse. [PDF]

PLoS ONE, 2012
BACKGROUND: A given tumor is usually dependent on the oncogene that is activated in the respective tumor entity. This phenomenon called oncogene addiction provides the rationale for attempts to target oncogene products in a therapeutic manner, be it by ...
Frank M Lehmann, Samantha Feicht, Florian Helm, Anna Maurberger, Camilla Ladinig, Ursula Zimber-Strobl, Ralf Kühn, Josef Mautner, Armin Gerbitz, Georg W Bornkamm   +9 more
doaj   +1 more source

Personalized Zebrafish Models for Fusion‐Positive Pediatric Sarcomas

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Clinical sequencing efforts have revolutionized our approaches to categorizing pediatric cancers in real time. This has dramatically improved our ability to profile pediatric tumors, identify actionable vulnerabilities, and influence clinical care.
Lisa H. Hall, Emma N. Harrison, Genevieve C. Kendall   +2 more
wiley   +1 more source

Antitumor Effect of Anti‐c‐Myc Aptamer‐Based PROTAC for Degradation of the c‐Myc Protein

Advanced Science
Targeting “undruggable” targets with intrinsically disordered structures is of great significance for the treatment of disease. The transcription factor c‐Myc controls global gene expression and is an attractive therapeutic target for multiple types of ...
Yuchun Wang, Gang Yang, Xinyu Zhang, Ruoling Bai, Deyu Yuan, Denghui Gao, Qianyu He, Yi Yuan, Xinghe Zhang, Junchuang Kou, Lihua Zheng, Yanxin Huang, Zhuo Tang, Yongli Bao, Xu Song, Yongyun Zhao   +15 more
doaj   +1 more source

In vivo inhibition of c-MYC in myeloid cells impairs tumor-associated macrophage maturation and pro-tumoral activities. [PDF]

PLoS ONE, 2012
Although tumor-associated macrophages (TAMs) are involved in tumor growth and metastasis, the mechanisms controlling their pro-tumoral activities remain largely unknown.
Oscar M Pello, Raphael Chèvre, Damya Laoui, Alba De Juan, Fidel Lolo, María Jesús Andrés-Manzano, Manuel Serrano, Jo A Van Ginderachter, Vicente Andrés   +8 more
doaj   +1 more source

Association Between Dinutuximab Beta Exposure and Post‐End‐of‐Treatment Survival in Neuroblastoma: A Weighted Patient‐Level Analysis of Three Clinical Studies

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Objectives The association between exposure to dinutuximab beta (DB) and event‐free survival (EFS) or overall survival (OS) of neuroblastoma patients was assessed using data collected during three clinical trials (five cohorts). Methods A systematic review (March 2026) was conducted to identify relevant studies (prospective; registered DB ...
Przemysław Holko, Holger N. Lode, Alberto Garaventa, Carla Manzitti, Roberto Luksch, Dominique Valteau‐Couanet, Marion Gambart, John Anderson, Juliet Gray, Adela Canete, Lucas Moreno, Aleksandra Wieczorek, Cormac Owens, Shifra Ash, Isaac Yaniv, Genevieve Laureys, Hans Loibner, Katarzyna Śladowska, Ruth Ladenstein, Paweł Kawalec   +19 more
wiley   +1 more source